Company · founded 2003

Sanaria

Rockville, United States · sanaria.com

Manage this page

Citations, last 5 years: 705
Works, last 5 years: 121
h-index: 156
Scientists listed: 10
Grants since 2016: 74

Grants received

2017–2024 · research · R44

Automating mosquito microdissection for a malaria PfSPZ vaccine

Sumana Chakravarty · Sanaria · funded by National Institutes of Health

$1MMalaria Research and Control

2017–2020 · research · R44

Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture

Peter F. Billingsley · Sanaria · funded by National Institutes of Health

$998.8k

2017–2020 · research · R44

Automating mosquito microdissection for a malaria PfSPZ vaccine

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$997.6k

2017–2025 · research · R44

Automating mosquito microdissection for a malaria PfSPZ vaccine

Sumana Chakravarty · Sanaria · funded by National Institutes of Health

$957.9kMalaria Research and Control

2017–2020 · research · R44

Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture

Peter F. Billingsley · Sanaria · funded by National Institutes of Health

$981.7k

2017–2024 · research · R44

Automating mosquito microdissection for a malaria PfSPZ vaccine

Sumana Chakravarty · Sanaria · funded by National Institutes of Health

$966.4kMalaria Research and Control

2017–2021 · research · R44

Automating mosquito microdissection for a malaria PfSPZ vaccine

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$975.7k

2017–2020 · research · R44

Automating mosquito microdissection for a malaria PfSPZ vaccine

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$987.6k

2016–2024 · research · R44

Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites

Sumana Chakravarty · Sanaria · funded by National Institutes of Health

$961.3kMalaria Research and Control

2016–2025 · research · R44

A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine

Sumana Chakravarty · Sanaria · funded by National Institutes of Health

$999.3kMalaria Research and Control

2016–2019 · research · R44

A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$1MMalaria Research and Control

2016–2023 · research · R44

Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$999kMalaria Research and Control

2016–2025 · research · R44

A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine

Sumana Chakravarty · Sanaria · funded by National Institutes of Health

$968.2kMalaria Research and Control

2016–2020 · research · R44

A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$1MMalaria Research and Control

2016–2019 · research · R44

A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$1MMalaria Research and Control

2016–2019 · research · R43

Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites (PvSPZ Challenge) for controlled human malaria infection (CHMI)

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$300kMalaria Research and Control

2016–2025 · research · R44

A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine

Sumana Chakravarty · Sanaria · funded by National Institutes of Health

$968.4kMalaria Research and Control

2016–2023 · research · R44

Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$977.4kMalaria Research and Control

2016–2027 · cooperative agreement · U44

Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites

Sumana Chakravarty · Sanaria · funded by National Institutes of Health

$995.5kMalaria Research and Control

2016–2018 · research · R43

Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites (PvSPZ Challenge) for controlled human malaria infection (CHMI)

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$300kMalaria Research and Control

2016–2027 · cooperative agreement · U44

Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites

Sumana Chakravarty · Sanaria · funded by National Institutes of Health

$1M

2010–2023 · research · R44

Cryopreservation of Anopheles Embryos

Peter F. Billingsley · Sanaria · funded by National Institutes of Health

$962.1kMalaria Research and Control

2010–2023 · research · R44

In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$965.7kMalaria Research and Control

2010–2024 · research · R44

Cryopreservation of Anopheles Embryos

Peter F. Billingsley · Sanaria · funded by National Institutes of Health

$966.8kMalaria Research and Control

2010–2023 · research · R44

In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$1MMalaria Research and Control

2010–2025 · research · R44

In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$947.1kMalaria Research and Control

2010–2023 · research · R44

Cryopreservation of Anopheles Embryos

Peter F. Billingsley · Sanaria · funded by National Institutes of Health

$1,000kMalaria Research and Control

2008–2020 · grant · SB1

Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$989.9k

2008–2021 · grant · SB1

Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$977.6k

2008–2020 · grant · SB1

Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$996.3k

2004–2023 · grant · SB1

PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$998.8k

2004–2020 · research · R44

Universal Attenuated Sporozoite Vaccine and Challenge System

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$951.4kMalaria Research and Control

2004–2023 · grant · SB1

PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$999.6k

2004–2023 · grant · SB1

PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization

Stephen Lev Hoffman · Sanaria · funded by National Institutes of Health

$974k